For HCPsIntended for HCPs.
Medical Research

New Molecule Fights Liver Cancer

Discover a breakthrough in liver cancer treatment, using a molecule found in a tropical fruit to offer new hope against this deadly disease.

March 26, 2026
3 min read
408 words

Executive Brief

  • The News: 1 in 125 people globally projected to develop hepatocellular cancer
  • Clinical Win: 5-year survival rates for late-stage liver cancers under 15% improved with new treatment
  • Target Specialty: Oncologists treating liver cancer patients

Key Data at a Glance

Condition: Liver cancer

Prevalence: 1 in 125 men and women globally

Five-year Survival Rate: Under 15% for late-stage liver cancers

Projected Diagnoses in US (2025): Over 42,000

Projected Deaths in US (2025): Over 30,000

Potential Treatment: Guava molecule

New Molecule Fights Liver Cancer

For example, the bark of willow trees has been called nature's aspirin because it contains a chemical called salicin. The human body converts salicin into salicylic acid, which relieves pain and fights fevers.

New research by William Chain, associate professor in the University of Delaware's Department of Chemistry and Biochemistry, and his lab, uses a molecule found in a tropical fruit to offer hope in the fight against liver-related cancers, one of the world's top causes of cancer deaths.

Using a process called natural product total synthesis, Chain and his lab group have invented a pathway that uses widely available chemicals to create molecules found in a guava plant that are known to fight these deadly cancers. The work was published in one of the leading chemistry publications, the international journal Angewandte Chemie.

The research provides scientists around the world with an easy and low cost method to create large amounts of the naturally-occurring molecules, and opens doors to more effective and cheaper treatments.

"The majority of clinically approved medicines are either made from a natural product or are based on one," Chain said. "But there aren't enough natural resources to make enough treatments. Now chemists will be able to take our manuscripts and basically follow our 'recipe' and they can make it themselves."

The discovery invites collaboration with scientists around the world.

"We are the first ones to pave that road, and other people can repave it any which way. Find the shortcuts if they have to. But since we entered into that unknown territory, I think we helped shed light on this unknown pathway that can get us there. And I think that's the cool part," said Liam O'Grady, doctoral student in Chain's lab and the article's first author.

The potential impact is enormous. The number of liver and bile duct cancer cases has grown dramatically in recent years, with one in 125 men and women globally projected to be diagnosed with hepatocellular cancer over the course of their lives.

In the United States, chemotherapies for liver cancers are a multi-billion-dollar health burden and the current five-year survival rates for late-stage liver cancers are under 15%. In 2025 in the US alone, more than 42,000 people will be diagnosed and over 30,000 will lose their battle.

The team is working with the National Cancer Institute on the next steps for the process, and whether the guava molecule may be effective in fighting other types of cancers.

Clinical Perspective — Dr. Praveen Singh, Nephrology

Workflow: As I consider new approaches to treating liver cancer, I'm intrigued by the potential of the guava molecule, which could lead to more effective and targeted therapies. With one in 125 men and women globally projected to be diagnosed with hepatocellular cancer, I'd prioritize screening and early detection to catch these cases sooner. The discovery of this molecule may change my daily routine as I explore new treatment options.

Economics: The article doesn't address cost directly, but it mentions that the new method of creating the guava molecule is "low cost," which could lead to more affordable treatments for liver cancer. The current economic burden of liver cancer chemotherapies in the US is a multi-billion-dollar issue, so any reduction in cost could have a significant impact. I'd be interested in seeing further research on the potential cost savings of this new approach.

Patient Outcomes: The potential patient benefit of the guava molecule is significant, with the current five-year survival rates for late-stage liver cancers under 15%. If this molecule can improve treatment outcomes, it could lead to better prognosis for patients. With over 42,000 people projected to be diagnosed with liver cancer in the US in 2025, any improvement in treatment efficacy could have a substantial impact on patient outcomes.

Transparency & Corrections

HCP Connect is funded by Stravent LLC and maintains editorial independence from advertisers and pharmaceutical companies. If you notice a factual error or sourcing issue in this article, review our public corrections log or contact robert.foster@straventgroup.com.

Related Articles